Estramustine phosphate oral
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Capsules containing estramustine phosphate
Drugs List
Therapeutic Indications
Uses
Carcinoma - prostate
Carcinoma of the prostate, especially in cases unresponsive to, or relapsing after, treatment by conventional oestrogens (stilbestrol, polyestradiol phosphate, etc) or by orchidectomy.
Dosage
Adults
The standard starting dose is 4 to 6 capsules (560 to 840 mg of estramustine phosphate) per day in divided doses.
Dosage should be adjusted according to response and gastrointestinal tolerance to a range of 1 to 10 capsules (140 to 1,400 mg of estramustine phosphate) per day.
Elderly
The standard starting dose is 4 to 6 capsules (560 to 840 mg of estramustine phosphate) per day in divided doses.
Dosage should be adjusted according to response and gastrointestinal tolerance to a range of 1 to 10 capsules (140 to 1,400 mg of estramustine phosphate) per day.
Administration
For oral administration, in divided doses not less than 1 hour before or 2 hours after meals.
Contraindications
Children under 18 years
Females
Peptic ulcer
Severe cardiovascular disorder
Severe hepatic disorder
Thromboembolic disorder
Thrombosis
Precautions and Warnings
Cardiovascular disorder
Cerebrovascular disorder
Congestive cardiac failure
Diabetes mellitus
Epileptic disorder
Hepatic impairment
History of thromboembolic disorder
History of thrombosis
Hypercalcaemia
Hypertension
Ischaemic heart disease
Metabolic bone disease
Migraine
Osteoblastic metastases
Porphyria
Renal impairment
Thrombophlebitis
Administration of live vaccines is not recommended
Consult local policy on the safe use of oral anti-cancer drugs
Treatment to be administered by or under supervision of specialist
Monitor blood pressure pre-treatment and periodically thereafter
Perform liver function tests before commencing therapy and during therapy
Monitor blood counts regularly
Monitor blood glucose closely in patients with diabetes mellitus
Monitor serum calcium levels
May affect results of some laboratory tests
Discontinue if angioneurotic oedema occurs
Avoid giving oral dose at same time as food, antacids or mineral supplement
Male: Ensure adequate contraception during treatment
Pregnancy and Lactation
Pregnancy
Not applicable - not indicated for use in women.
Women of child bearing potential should use adequate contraception during sexual intercourse with a man being treated with estramustine phosphate.
Lactation
Not applicable - not indicated for use in women.
Side Effects
Anaemia
Angioneurotic oedema
Confusion
Congestive cardiac failure
Depression
Diarrhoea
Fluid retention
Gynaecomastia
Headache
Hepatic impairment
Hypersensitivity reactions
Hypertension
Impotence
Ischaemia
Laryngeal oedema
Lethargy
Leukopenia
Muscle weakness
Myocardial infarction
Nausea
Quincke's oedema
Rash
Thrombocytopenia
Thromboembolic disorders
Vomiting
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: November 2013
Reference Sources
Martindale: The Complete Drug Reference, 37th edition (2011) ed. Sweetman, S. Pharmaceutical Press, London.
Summary of Product Characteristics: Estracyt capsules. Pharmacia Limited. July 2013.
Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.